Merck (MRK) Total Non-Current Liabilities (2009 - 2026)
Merck (MRK) reported Total Non-Current Liabilities of $75.1 billion for Q1 2026, up 25.05% year-over-year from $60.1 billion in Q1 2025, and down 1.91% quarter-over-quarter from $76.6 billion in Q4 2025.
Merck (MRK) Total Non-Current Liabilities (2009 - 2026) Analysis & Trends
Merck (MRK) has 17 years of Total Non-Current Liabilities data on file, last reported at $75.1 billion in Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $75.1 billion, up 25.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $75.1 billion (up 25.05% YoY), and the FY2025 annual result was $76.6 billion, changed N/A from the prior year.
- Total Non-Current Liabilities eased to $75.1 billion in Q1 2026 per MRK's latest filing, from $76.6 billion in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $76.6 billion in Q4 2025 and troughed at $600.0 million in Q1 2022.
- A 5-year average of $24.9 billion and a median of $675.0 million in 2022 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities changed 0.0% in 2023, then jumped 7908.93% in 2025.
- A 5-year view of Total Non-Current Liabilities shows it stood at $600.0 million in 2022, then advanced by 25.0% to $750.0 million in 2023, then changed by 0.0% to $750.0 million in 2024, then soared by 10109.6% to $76.6 billion in 2025, then fell by 1.91% to $75.1 billion in 2026.
- Business Quant data shows MRK's Total Non-Current Liabilities at $75.1 billion in Q1 2026, $76.6 billion in Q4 2025, and $70.0 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | -31.03 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 48.74 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 119.22 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 108.96 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 75.11 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 80.55 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 31.56 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 113.51 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 61.52 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | 100.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 75.11 Bn |
| Dec 31, 2025 | 76.57 Bn |
| Sep 30, 2025 | 69.98 Bn |
| Jun 30, 2025 | 61.43 Bn |
| Mar 31, 2025 | 60.07 Bn |
| Mar 31, 2024 | 750.00 Mn |
| Dec 31, 2023 | 750.00 Mn |
| Sep 30, 2023 | 600.00 Mn |
| Jun 30, 2023 | 600.00 Mn |
| Mar 31, 2023 | 600.00 Mn |
| Dec 31, 2022 | 600.00 Mn |
| Sep 30, 2022 | 600.00 Mn |
| Jun 30, 2022 | 600.00 Mn |
| Mar 31, 2022 | 600.00 Mn |
| Mar 31, 2021 | 400.00 Mn |
| Dec 31, 2020 | 600.00 Mn |
| Sep 30, 2020 | 400.00 Mn |
| Jun 30, 2020 | 570.00 Mn |
| Mar 31, 2020 | 375.00 Mn |
| Dec 31, 2019 | 375.00 Mn |